Prognostic value of p53 protein expression for patients with gastric cancer: A multivariate analysis

British Journal of Cancer

Volumn 79, Issue 7-8, 1999, Pages 1255-1261

  Maehara, Y ^a   Tomoda, M ^a   Hasuda, S ^a   Kabashima, A ^a   Tokunaga, E ^a   Kakeji, Y ^a   Sugimachi, K ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Gastric cancer; Multivariate analysis; p53 expression; Prognosis

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGRESSION ANALYSIS; STOMACH CANCER; SURVIVAL RATE;

ANALYSIS OF VARIANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROGNOSIS; RECURRENCE; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR NEOPLASMS;

EID: 0032983645     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690201     Document Type: Article

References (61)

1. Allred DC, Clark GM, Elledge R, Fuqua SAW, Brown RW, Chamness GC, Osborne CK and McGuire WL (1993) Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85: 200-206
2. Banks L, Matlashewski M and Crawford L (1986) Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 159: 529-534
3. Bell SM, Scott N, Cross D, Sagar P, Lewis FA, Blair GE, Taylor GR, Dixon MF and Quirke P (1993) Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 104: 57-64
4. Bozzetti F, Bonfanti G, Bufalino R, Menotti V, Persann S, Andreola S, Doci R and Gennari L (1982) Adequacy of margins of resection in gastrectomy for cancer. Ann Surg 196: 685-690
5. Brambilla E, Gazzeri S, Moro D, de Fromentel CC, Gouyer V, Jacrot M and Brambilla C (1993) Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol 143: 199-210
6. Caelles C, Helmberg A and Karin M (1994) p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370: 220-223
7. Carson DA and Lois A (1995) Cancer progression and p53. Lancet 346: 1009-1011
8. Chang F, Syrjänen S and Syrjänen K (1995) Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 13: 1009-1022
9. Chin K-V, Ueda K, Pastan I and Gottesman MH (1992) Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 255: 459-462
10. Cox DR (1972) Regression models and life tables. J R Stat Soc Series B 34: 187-220
11. Cross SM, Sanchez CA, Morgan CA, Schimke MK, Ramel S, Idzerda RL, Raskind WH and Reid BJA (1995) A p53-dependent mouse spindle checkpoint. Science 267: 1353-1356
12. Dixon WJ (1988) BMDP Statistical Software. University of California Press: Berkeley, CA
13. Elledge RM, Gray R, Mansour E, Yu Y, Clark GM, Ravdin P, Osborne CK, Gilchrist K, Davidson NE, Robert N, Tormey DC and Allred DC (1995) Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 87: 1254-1256
14. Finlay CA, Hinds PW, Tan T-H, Eliyahu D, Oren M and Levine AJ (1988) Activating mutations for transformation by p53 produce a gene product that forms an hsc 70-p53 complex with an altered half-life. Mol Cell Biol 8: 531-539
15. Furihata M, Ohtsuki Y, Sonobe H, Shuin T, Yamamoto A, Terao N and Kuwahara M (1988) Prognostic significance of cyclin E and p53 protein overexpression in carcinoma of the renal pelvic and ureter. Br J Cancer 77: 783-788
16. Gabbert HE, Müller W, Schneiders A, Meier S and Hommel G (1995) The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 76: 720-726
17. Gannon JV, Greaves R, Iggo R and Lane DP (1990) Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9: 1595-1602
18. Govender D, Harilal P, Hadley GP and Chetty R (1998) p53 protein expression in nephroblastomas: a predictor of poor prognosis. Br J Cancer 77: 314-318
19. Harris CC and Hollstein M (1993) Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329: 1318-1327
20. Japanese Research Society for Gastric Cancer (1981) The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification. Jpn J Surg 11: 127-139. Part II. Histological classification of gastric cancer. Jpn J Surg II: 140-145
21. Japanese Research Society for Gastric Cancer (1981) The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification. Jpn J Surg 11: 127-139. Part II. Histological classification of gastric cancer. Jpn J Surg II: 140-145
22. Japanese Research Society for Gastric Cancer (ed) (1993) The General Rules for Gastric Cancer Study (in Japanese), 12th edn. Kanehara and Co.: Tokyo, Japan
23. Joypaul BV, Hopwood D, Newman EL, Qureshi S, Grant A, Ogston SA, Lane DP and Cuschieri A (1994) The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. Br J Cancer 69: 943-946
24. Kakeji Y, Korenaga D, Tsujitani S, Baba H, Anai H, Maehara Y and Sugimachi K (1993) Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes. Br J Cancer 67: 589-593
25. Kang S-M, Maeda K, Onoda N, Chung Y-S, Nakata B, Nishiguchi Y and Sowa M (1997) Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis. Int J Cancer 74: 502-507
26. Kawasaki S (1975) A clinicopathological study on upward intramural extension of cancer of the stomach (in Japanese with English abstract). Fukuoka Acta Med 66: 1-23
27. Kim J-H, Takahashi T, Chiba I, Park J-G, Birrer MJ, Roh JK, Lee HD, Kim J-P, Minna JD and Gazdar AF (1991) Occurrence of p53 gene abnormalities in gastric carcinoma tumors and cell lines. J Natl Cancer Inst 83: 938-943
28. Koechli OR, Schaer GN, Seifert B, Hornung R, Haller U, Eppenberger U and Mueller H (1994) Mutant p53 protein associated with chemosensitivity in breast cancer specimens. Lancet 344: 1647-1648
29. Korenaga D, Okamura T, Baba H, Saito A and Sugimachi K (1988) Results of resection of gastric cancer extending to adjacent organs. Br J Surg 75: 12-15
30. Levine AJ, Momand J and Finlay CA (1991) The p53 tumour suppressor gene. Nature 351: 453-456
31. Levine AJ, Perry ME, Chang A, Silver A, Dittmer D, Wu M and Welsh D (1994) The 1993 Walter Hubert Lecture. The role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 69: 409-416
32. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE and Jacks T (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810
33. Maehara Y, Okuyama T, Moriguchi S, Orita H, Kusumoto H, Korenaga D and Sugimachi K (1992a) Prophylactic lymph node dissection in patients with advanced gastric cancer promotes increased survival time. Cancer 70: 392-395
34. Maehara Y, Orita H, Okuyama T, Moriguchi S, Tsujitani S, Korenaga D and Sugimachi K (1992b) Predictors of lymph node metastasis in early gastric cancer. Br J Surg 79: 245-247
35. Maehara Y, Okuyama T, Oshiro T, Baba H, Anai H, Akazawa K and Sugimachi K (1993) Early carcinoma of the stomach. Surg Gynecol Obstet 177: 593-597
36. Maehara Y, Okuyama T, Kakeji Y, Endo K, Yamamoto M and Sugimachi K (1995) A tumour-associated cell-surface glycoprotein accompanying p53 overexpression and higher growth potential for gastric cancer. Br J Cancer 71: 999-1002
37. Martin HM, Filipe MI, Morris RW, Lane DP and Silvestre F (1992) p53 expression and prognosis in gastric carcinoma. Int J Cancer 50: 859-862
38. McLaren R, Kuzu I, Dunnill M, Harris A, Lane D and Gatter KC (1992) The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 66: 735-738
39. Mönig SP, Eidt S, Zirbes TK, Stippel D, Baldus SE and Pichlmaier H (1997) p53 expression in gastric cancer. Clinicopathological correlation and prognostic significance. Dig Dis Sci 42: 2463-2467
40. Motojima K, Furui J, Kohara N, Ito T and Kanematsu T (1994) Expression of p53 protein in gastric carcinomas is not independently prognostic. Surgery 116: 890-895
41. Narayana A, Vaughan ATM, Gunaratne S, Kathuria S, Walter SA and Reddy SP (1998) Is p53 an independent prognostic factor in patients with laryngeal carcinoma? Cancer 82: 286-291
42. Oiwa H, Maehara Y, Ohno S, Sakaguchi Y, Ichiyoshi Y and Sugimachi K (1995) Growth pattern and p53 overexpression in patients with early gastric cancer. Cancer 75: 1454-1459
43. Piffkò J, Bànkfalvi À, Tory K, Füzesi L, Bryne M, Öfner D, Kusch F, Joos U and Schmid KW (1998) Molecular assessment of p53 abnormalities at the invasive front of oral squamous cell carcinomas. Head Neck 20: 8-15
44. Porter PL, Gown AM, Kramp SG and Coltrerea MD (1992) Widespread p53 overexpression in human malignant tumors. Am J Pathol 140: 145-153
45. Quinlan DC, Davidson AG, Summers CL, Warden HE and Doshi HM (1992) Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52: 4828-4831
46. Sakaguchi T, Watanabe A, Sawada H, Yamada Y, Yamashita J, Matsuda M, Nakajima M, Miwa T, Hirao T and Nakano H (1998) Prognostic value of cyclin E and p53 expression in gastric carcinoma. Cancer 82: 1238-1243
47. Sarbia M, Porschen R, Borchard F, Horstmann O, Willers R and Gabbert HE (1994) p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer 74: 2218-2223
48. Schneider BG, Hilsenbeck SG, Hensel CH, Pekkel V, Shelton CH, Rodríguez-Martínez HA, Gutiérrez-Díaz CME, Pulitzer DR and Allred DC (1994) p53 mutations in gastric and colorectal cancers in Texas Hispanics versus Anglos. Virchows Arch 424: 187-193
49. Shimaya K, Shiozaki H, Inoue M, Tahara H, Monden T, Shimano T and Mori T (1993) Significance of p53 expression as prognostic factor in oesophageal squamous cell carcinoma. Virchows Arch A Pathol Anat 422: 271-276
50. Sobin LH and Wittekind C (1997) TNM Classification of Malignant Tumour, 5th edn. John Wiley & Sons: New York, NY
51. Soussi T, Legros Y, Lubin R, Ory K and Schlichtholz B (1994) Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer 57: 1-9
52. Starzynska T, Bromley M, Ghosh A and Stern PL (1992) Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 66: 558-562
53. Sugimachi K, Maehara Y, Ogawa M, Kakegawa T and Tomita, M (1997) Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer. Cancer Chemother Pharmacol 40: 233-238
54. Suto T, Sugai T, Nakamura S, Funato O, Nitta H, Sasaki R, Kanno S and Saito K (1998) Assessment of the expression of p53, MIB-1 (Ki-67 antigen), and argyrophilic nucleolar organizer regions in carcinoma of the extrahepatic bile duct. Cancer 82: 86-95
55. Takahashi Y, Bucana CD, Cleary KR and Ellis LM (1998) p53, vessel count, and vascular endothelial growth factor expression in human colon cancer. Int J Cancer 79: 34-38
56. Thor AD, Moore II DH, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen L-C, Mayall BH and Smith HS (1992) Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 84: 845-855
57. Uchino S, Noguchi M, Ochiai A, Saito T, Kobayashi M and Hirohashi S (1993) p53 mutation in gastric cancer: a genetic model for carcinogenesis is common to gastric and colorectal cancer. Int J Cancer 54: 759-764
58. Vogelstein B and Kinzler KW (1992) p53 function and dysfunction. Cell 70: 523-526
59. Wynford-Thomas D (1992) p53 in tumour pathology: can we trust immunocytochemistry? J Pathol 166: 329-330
60. Yamaguchi A, Nakagawara G, Kurosaka Y, Nishimura G, Yonemura Y and Miyazaki I (1993) p53 immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance. Br J Cancer 68: 399-402
61. Yokozaki H, Kuniyasu H, Kitadai Y, Nishimura K, Todo H, Ayhan A, Yasui W, Ito H and Tahara E (1992) p53 point mutations in primary gastric carcinomas. J Cancer Res Clin Oncol 119: 67-70